Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
BACKGROUND
Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown.


RESULTS
This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0+/-1.6 mm(2) vs +3.4+/-1.7 mm(2), P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group.


CONCLUSIONS
Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome.
Kim
Sung Soo
SS
The Heart Center of Chonnam National University Hospital, Dong-gu, Gwangju 501-757, Korea.
Hong
Young Joon
YJ
Jeong
Myung Ho
MH
Kim
Weon
W
Kim
Hyun-Kuk
HK
Ko
Jum Suk
JS
Lee
Min Goo
MG
Sim
Doo Sun
DS
Park
Keun Ho
KH
Yoon
Nam Sik
NS
Yoon
Hyun Ju
HJ
Kim
Kye Hun
KH
Park
Hyung Wook
HW
Kim
Ju Han
JH
Ahn
Youngkeun
Y
Cho
Jeong Gwan
JG
Park
Jong Chun
JC
Song
Sun-Jung
SJ
Cho
Dong Lyun
DL
Kang
Jung Chaee
JC
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000401:mortality / Q000517:prevention & control; D003328:Coronary Thrombosis / Q000401:mortality / Q000517:prevention & control; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D008670:Metals; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab